Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 October 16, 2024 • 12:54 PM EDT
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences October 16, 2024 • 11:58 AM EDT
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 October 15, 2024 • 4:15 PM EDT
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 October 14, 2024 • 8:30 AM EDT
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update October 8, 2024 • 7:00 AM EDT
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 September 20, 2024 • 9:25 AM EDT
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences September 18, 2024 • 8:30 AM EDT
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study September 11, 2024 • 8:30 AM EDT
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. September 9, 2024 • 8:30 AM EDT
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer August 19, 2024 • 9:00 AM EDT